Vector Labs Ab03946-10.0 Anti-CD69 [2.8], Human IgG1, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 2.8
Synonyms: AIM; BL-AC/P26; EA1; CLEC2C; GP32/28; MLR-3; Early activation antigen CD69; Activation inducer molecule; C-type lectin domain family 2 member C; Early T-cell activation antigen p60; Leukocyte surface antigen Leu-23
Amount: 100 μg
Application Codes Clone: FC; in vivo; therapeutic
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody binds human CD69. CD69 (cluster of differentiation 69), a membrane bound type II C-lectin disulfide–linked homodimer receptor, which is expressed on different leukocytes, including newly-activated lymphocytes, certain subtypes of memory T-cells, infiltrating lymphocytes isolated from patients with chronic inflammatory disorders, and regulatory T-cells. It is involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets.
Application Notes: This antibody can be used for the analysis of CD69 expressed on the surface of cell surface using flow cytometry (PMID: 16983725). This antibody was used as a control antibody in in vivo mouse experiments as it does not bind mouse CD69 (PMID: 16983725; 27151919). This antibody was used in a study to show control on vaccinia virus (VACV) infection in both preventive and therapeutic treatment for transgenic mice expressing human CD69. Treatment in human-CD69 transgenic mouse model with the anti-huCD69-2.8 MAb could affect the primary adaptive response to VACV infection by increasing the number of activated T cells in the periphery (PMID: 31315995). In vivo CD69 targeting in mice expressing human CD69 induced rapid and massive mobilization of bone marrow leukocytes, which was inhibited by desensitization to S1P with FTY720. The treatment highly increased LSK and CLP cell proliferation and numbers, both in the periphery and in the bone marrow, and also augmented S1P1 and CXCR4 expression (PMID: 29483712).

Product Class:	Purified
Clone ID:	2.8
Synonyms:	AIM; BL-AC/P26; EA1; CLEC2C; GP32/28; MLR-3; Early activation antigen CD69; Activation inducer molecule; C-type lectin domain family 2 member C; Early T-cell activation antigen p60; Leukocyte surface antigen Leu-23
Amount:	100 μg
Application Codes Clone:	FC; in vivo; therapeutic
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody binds human CD69. CD69 (cluster of differentiation 69), a membrane bound type II C-lectin disulfide–linked homodimer receptor, which is expressed on different leukocytes, including newly-activated lymphocytes, certain subtypes of memory T-cells, infiltrating lymphocytes isolated from patients with chronic inflammatory disorders, and regulatory T-cells. It is involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets.
Application Notes:	This antibody can be used for the analysis of CD69 expressed on the surface of cell surface using flow cytometry (PMID: 16983725). This antibody was used as a control antibody in in vivo mouse experiments as it does not bind mouse CD69 (PMID: 16983725; 27151919). This antibody was used in a study to show control on vaccinia virus (VACV) infection in both preventive and therapeutic treatment for transgenic mice expressing human CD69. Treatment in human-CD69 transgenic mouse model with the anti-huCD69-2.8 MAb could affect the primary adaptive response to VACV infection by increasing the number of activated T cells in the periphery (PMID: 31315995). In vivo CD69 targeting in mice expressing human CD69 induced rapid and massive mobilization of bone marrow leukocytes, which was inhibited by desensitization to S1P with FTY720. The treatment highly increased LSK and CLP cell proliferation and numbers, both in the periphery and in the bone marrow, and also augmented S1P1 and CXCR4 expression (PMID: 29483712).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews